References
- Lasica M, Anderson MA. Review of Venetoclax in CLL, AML and Multiple Myeloma. J Pers Med. 2021 May 24;11(6):463. doi: 10.3390/jpm11060463. PMID: 34073976; PMCID: PMC8225137.
- Bruzzese A, Martino EA, Mendicino F, et al. Venetoclax in acute myeloid leukemia. Expert Opin Investig Drugs. 2023 Apr;32(4):271–6. doi: 10.1080/13543784.2023.2193679. Epub 2023 Mar 23. PMID: 36933006
- Birkinshaw RW, Gong JN, Luo CS, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1. PMID: 31160589; PMCID: PMC6547681
- Hu N, Guo Y, Xue H, et al. Preclinical characterization of BGB-11417, a potent and selective bcl-2 inhibitor with superior anti-tumour activities in haematological tumour models. Cancer Res. 2020;80(16_Supplement):3077. doi: 10.1158/1538-7445.AM2020-3077
- Li C, Wei J, Zhou K, et al. A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies. J Clin Oncol. 2023;41(16_suppl):7558–7558. doi: 10.1200/JCO.2023.41.16_suppl.7558
- Quach H, Sborov D, Kazandjian D, et al. Sonrotoclax (BGB-11417) in combination with Dexamethasone for the treatment of Relapsed/Refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose. Proceeding of 65th ASH annual conference and exposition; 2023 Dec 9–15; San Diego, Caslifornia
- Quach H, Rajagopal R, Spencer A, et al. Preliminary safety of a Bcl-2 Inhibitor, bgb-11417, in patients with Relapsed/Refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study. Blood. 2022;140(Supplement 1):7269–7271. doi: 10.1182/blood-2022-169666
- Soumerai JD, Opat S, Cheah CY, et al. A phase 1 study with the novel bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-Cell malignancies: preliminary data. Abstract. Presented at 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), 2022, September 28-October 1. Houston, Texas.
- Tedeschi A, Cheah CY, Opat SS, et al. Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with Relapsed/Refractory marginal zone lymphoma: data from an ongoing phase 1 study. Proceeding of 65th ASH annual conference and exposition; 2023 Dec 9-15; San Diego, California
- Tam CS, Anderson MA, Lasica M, et al. Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study. Proceeding of 65th ASH Annual Conference and Exposition; 2023 Dec 9-15; San Diego, California
- Shortt J, Montesinon P, Et a TS. Preliminary safety and efficacy of bgb-11417, a Novel Bcl-2 Inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML). Blood. 2022;140(Supplement 1):3329–3332. doi: 10.1182/blood-2022-166937
- Tiong IS, Nguyen T, Teh C, et al. BAX mutated clonal hematopoiesis arises following treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and non-Hematological neoplasms. Proceeding of 65th ASH annual conference and exposition; 2023 Dec 9-15; San Diego, California.